OOIR: Observatory of International Research

Papers

(The H4-Index of Journal of Cystic Fibrosis is 36. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)

Article	Citations
EPS10.06 Highly-effective CFTR modulation is associated with greater height and peak lung function in children with cystic fibrosis	250
EPS8.02 Evolving physiotherapy airway clearance technique (ACT) interventions during cystic fibrosis (CF) pregnancy in the variant specific therapy (VST) era	124
P172 Oscillometry: assessment of bronchial obstruction in children with cystic fibrosis	92
P078 Hyperacute response to cystic fibrosis transmembrane conductance regulator modulation	91
P402 Separation anxiety or a Kaftrio side effect? Implementation of cognitive behavioural therapy strategies with a young child with cystic fibrosis (CF): A clinical case study	90
P408 The halo effect in cystic fibrosis: when educated patients in turn educate their family carers	82
EPS10.07 Exacerbation characteristics and clinical outcomes in the elexacaftor/tezacaftor/ivacaftor era: same-same but different?	81
WS08.03 How does elexacaftor/tezacaftor/ivacaftor affect improvement in exercise capacity and body composition in adults with cystic fibrosis who have completed an exercise intervention?	79
P131 Effect of deprescribing from inhaled corticosteroids in people with cystic fibrosis: challenges & opportunities for a target trial emulation using the UK CF Registry	78
WS15.05 Improvements in structural lung disease in people with CF aged 12 and above on elexacaftor/tezacaftor/ivacaftor are sustained for up to two years	75
P296 Characteristics of carbohydrate metabolism disorders in children with cystic fibrosis in the Moscow region	73
P109 Safety of elexacaftor/tezacaftor/ivacaftor in patients 6 through 18 years with cystic fibrosis and at least one F508del allele: a retrospective Italian multicenter study	69
WS13.03 Anti-inflammatory effects of elexacaftor/tezacaftor/ivacaftor in adults with cystic fibrosis heterozygous for F508del	67
463: Clearance of colonized bacterial species in CF patients before and after elexacaftor/tezacaftor/ivacaftor	64
410 Multidisciplinary collaboration for transition readiness and planning	63
460: Prevalence of antimicrobial resistance mutations in Mycobacterium abscessus and associations with in vitro susceptibility testing	57
465: Intestinal function and transit relates to microbial dysbiosis in the CF gut	57
491 The Cystic Fibrosis Questionnaire–Revised and body image in adults in the era of elexacaftor-tezacaftor-ivacaftor	56
568: Quantifying regional pulmonary ventilation changes pre-/postivacaftor treatment in same subject using hyperpolarized 3He MRI	49
620: Iterative screen identifies amphiphilic peptides that confer enhanced delivery of CRISPR-associated nucleases and adenine base editors to airway epithelia	48
524 Acid suppression therapy and associations with growth, gut microbiome, and early-onset lung disease in young children with cystic fibrosis	48
585: Development of a novel, cell-free, in vitro, high-throughput screening system for readthrough agents of nonsense mutations	48
488: Bile acids, bacterial colonization, and lung inflammatory markers in infants with cystic fibrosis	47
508: Extracellular vesicles mediate bacteria–immune cell interactions in the respiratory tract	45
P209 Physical fitness and habitual physical activity in children with cystic fibrosis - do they improve with elexacaftor/tezacaftor/ivacaftor therapy?	44

P221 Tension-free vaginal tape – a 15-year review of effect on urinary incontinence in patients with cystic fibrosis	43
353: Electrolyte transport properties assay revealed less carbachol-stimulated short-circuit current in cultured human small airway epithelia	42
372 Cystic fibrosis does exist in India! A successful approach to education and improving awareness of cystic fibrosis of physicians and caregivers in India	41
558 Development of a gene editing strategy to treat cystic fibrosisassociated liver disease	41
140: Oh gee! Time tested OGTT annual screening improvement: A single-center experience	39
670: F508del and G542X sheep models exhibit a severe cystic fibrosis phenotype, and their tracheal epithelial cells respond to human therapeutics in vitro	39
148: Sustainably implementing impactful pre-visit planning using the electronic health record	39
P029 Antisense oligonucleotide-based drug development for cystic fibrosis patients carrying the 2789+5 G-to-A splicing mutation	38
P052 Introduction of an innovative “pill-swallowing school” in a cystic fibrosis paediatric population within a tertiary centre	37
249 Pharmacological rescue of CFTR premature termination codon mutations by novel small molecules	37
54 Recombinant pyocins as emerging therapies against respiratory infections with Pseudomonas aeruginosa	36
13 Extended-interval dosing of amikacin against Mycobacterium abscessus reduces efficacy in vitro	36
100 Vancomycin demonstrates activity against Mycobacterium abscessus in combination with guideline-recommended antibiotics under physiologically relevant stress conditions	36
11 Examining antibiotic regimen spectrum and clinical outcomes of pulmonary exacerbation treatment	36
43 Bacteriophages that kill Pseudomonas aeruginosa induce heterogenous cellular responses in the airway epithelium	36